Abstract: Provided are methods and system for assessing a human subject's neurological and/or psychological status. The methods entail displaying visual tests to a human subject, wherein each of the visual tests includes a visual target signal, optionally with visual cue signals, for eliciting visual and, optionally, body part, movements by the subject. Following the display, the movements are then detected. The latency and/or correctness of such movements can then be used to assess the subject's neurological and/or psychological status. Also provided are methods and systems for assessing performance validity.
Type:
Grant
Filed:
March 10, 2014
Date of Patent:
August 30, 2022
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: An intracranial access device includes a housing having an operator-facing side and a patient-facing side and an opening therethrough extending from the operator-facing side to the patient-facing side. The device further includes at least one fastener configured to secure the device to a cranium of a patient. The device further includes a drill mounted to a surface of the housing and a cauterizer. The device may further include a number of sensors arranged on the patient-facing side of the housing and configured to identify a hemorrhage location.
Type:
Application
Filed:
July 16, 2020
Publication date:
August 18, 2022
Applicants:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Johns Hopkins University
Inventors:
David L. Brody, David Blodgett, Carissa Rodriguez, Timothy Sleasman, Michael J. Fitch, Adam Cohen, Max R. Basescu, Kevin C. Wolfe, Jared M. Wormley
Abstract: The invention relates to compounds, compositions and methods for activating, reactivating, reversing or preventing the deactivation of cholinesterases, such as acetylcholinesterase and butyrylcholinesterase.
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
May 31, 2022
Assignees:
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., The Government of the United States as Represented by the Secretary of the Army
Inventors:
Ilja Khavrutskii, Sven Anders Wallqvist
Abstract: The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.
Type:
Application
Filed:
April 27, 2018
Publication date:
May 26, 2022
Applicant:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Sheetij Dutta, Zoltan Beck, Carl Alving, Gary Matyas
Abstract: The present invention provides methods of preventing or reducing the risk of recurrence of endometrial and ovarian cancers which express low levels of folate binding protein (FBP) by administration of a vaccine containing an E39 peptide.
Type:
Grant
Filed:
January 16, 2018
Date of Patent:
May 24, 2022
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.
Type:
Grant
Filed:
August 10, 2020
Date of Patent:
May 17, 2022
Assignee:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
Type:
Application
Filed:
November 2, 2021
Publication date:
April 7, 2022
Applicants:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human Services
Inventors:
Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
Abstract: The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a therapeutically effective amount.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
April 5, 2022
Assignee:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Inventors:
Jishnu K. S. Krishnan, Aryan M. Namboodiri, John R. Moffett, Peethambaran Arun, Narayanan Puthillathu, Ranjini Vengilote
Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and methods of using those compositions of matter for the same are disclosed. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
Type:
Application
Filed:
December 16, 2021
Publication date:
March 31, 2022
Applicants:
The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
February 1, 2022
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
February 1, 2022
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.
Type:
Application
Filed:
June 28, 2021
Publication date:
December 23, 2021
Applicant:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Maria F. BRAGA, Vassiliki ARONIADOU-ANDERJASKA
Abstract: The present invention relates to methods of diagnosing traumatic brain injury (TBI) in a subject. The present invention also relates to methods of monitoring the progression of the TBI in a subject.
Type:
Application
Filed:
April 8, 2021
Publication date:
September 9, 2021
Applicants:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., University of Florida Research Foundation, Inc., Orlando Health, Inc., d/b/a Orlando Regional Medical Center
Inventors:
Radha K. MAHESHWARI, Nagaraja S. BALAKATHIRESAN, Manish BHOMIA, Kevin K. WANG, Linda PAPA
Abstract: Described herein are agents and methods for targeting antigen-specific B cells using engineered T cells, such as regulatory T cells or cytotoxic T cells, or bi-specific antibodies. The agents and methods can be used to reduce undesirable immune responses.
Type:
Grant
Filed:
October 6, 2016
Date of Patent:
August 17, 2021
Assignee:
The Henry M. Jackson Foundation for the Advancement of
Military Medicine, Inc.
Inventors:
David W. Scott, Yongchan Kim, Aihong Zhang
Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
Type:
Application
Filed:
April 24, 2019
Publication date:
August 5, 2021
Applicants:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israel Deaconess Medical Center, Inc., The Government of the United States as Represented by the Secretary of the Army
Inventors:
Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce
Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
Type:
Application
Filed:
January 29, 2021
Publication date:
July 29, 2021
Applicant:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Inventors:
Christopher C. Broder, Katharine N. Bossart
Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
June 29, 2021
Assignee:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Inventors:
Maria F. Braga, Vassiliki Aroniadou-Anderjaska
Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.
Type:
Application
Filed:
August 10, 2020
Publication date:
June 24, 2021
Applicant:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.